(Q46035514)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Vito Lorusso

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Gerardo Rosati

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Luigi Manzione

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Luca Frassineti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Teodoro Sava

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Eugenio Donato Di Paula

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Silvia Alonso

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Cora N Sternberg

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

language of work or name

English

0 references

publication date

1 June 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

2652-2659

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19396817%20AND%20SRC:MED&resulttype=core&format=json

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Gemcitabine in transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021

Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24313

7 January 2021